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Abstract  
Reproductive genetic carrier screening identifies couples with an increased chance of having 
children with autosomal and X-linked recessive conditions. Initially only offered for single 
conditions to people with a high priori risk, carrier screening is becoming increasingly offered 
to individuals/couples in the general population for a wider range of genetic conditions. 
Despite advances in genomic testing technology and greater availability of carrier screening 
panels, there is no consensus around which types of conditions to include in carrier screening 
panels. This study sought to identify which types of conditions parents of children with a 
genetic condition believe should be included in carrier screening. Participants (n=150) were 
recruited through Melbourne paediatric hospital outpatient clinics, the Genetic Support 
Network of Victoria (GSNV) and a databank of children with hearing loss. This study found that 
the majority of participants support offering carrier screening for: neuromuscular conditions 
(n=128/134, 95.5%), early fatal neurodegenerative conditions (n=130/141, 92.2%), chronic 
multi-system disorders (n=124/135, 91.9%), conditions which cause intellectual disability 
(n=128/139, 92.1%) and treatable metabolic conditions (n=120/138, 87.0%). Views towards 
the inclusion of non-syndromic hearing loss (n=88/135, 65.2%) and preventable adult-onset 
conditions (n=75/135, 55.6%) were more mixed. Most participants indicated that they would 
use reproductive options to avoid having a child with the more clinically severe conditions, but 
most would not do so for clinically milder conditions. A recurring association was observed 
between participants’ views towards carrier screening and their lived experience of having a 
child with a genetic condition. 
 





Reproductive genetic carrier screening (referred to as carrier screening hereafter) is 
the process by which people are screened to determine whether they have an 
increased chance of having a child with an inherited genetic condition. When two 
individuals are genetic carriers for the same autosomal recessive (AR) condition they 
have a one in four chance of having an affected pregnancy (1). If a woman is a genetic 
carrier for an X-linked recessive (XLR) condition, there is usually a one in four chance of 
having an affected son (1). Carrier screening can be offered either pre-pregnancy or in 
early pregnancy to enable utilisation of reproductive options. Previously, carrier 
screening has been limited to the most common genetic conditions and/or offered to 
individuals with a high priori risk due to family history or ethnic ancestry (2). Notable 
examples include haemoglobinopathy screening for sickle cell disease and alpha and 
beta thalassaemia, Tay Sachs disease (TSD) screening in Ashkenazi Jewish populations 
and cystic fibrosis screening for those with a family history (3);(4).  
 
Rapid developments in genomic technologies have led to the evolution of large 
carrier screening panels which is referred to as ‘expanded carrier screening’ (ECS), 
whereby couples can be tested simultaneously for hundreds of AR and XLR conditions 
(5). Whilst practice varies widely with respect to carrier screening, a number of 
countries have policy/position statements supporting the offer of reproductive genetic 
carrier screening to all people planning a pregnancy or in early pregnancy (6) (7) (8). 
Despite a shift towards endorsing carrier screening, there is no clear consensus around 
which types of conditions should be included in carrier screening panels.  
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Consideration of which conditions to include has raised ethical concerns from 
both public and professional standpoints. Previous studies have highlighted the 
complexities associated with determining where to draw the line, specifically regarding 
the inclusion of conditions with variable presentation, later onset and milder 
phenotypes (9) (10). Disability rights communities have flagged potential negative 
impacts, with some believing that offering screening for particular conditions could 
impose a lesser societal value on those with the condition (11). This reinforces the 
importance of including families with experience of a genetic condition in discussions 
about carrier screening.  
 
Lived experience of a particular condition has been shown to underscore 
attitudes towards screening. Boardman, Young, Warren & Griffiths (2017) found a 
difference in views towards prenatal screening for SMA depending on which SMA type 
the individual/family member was affected by or had experience of. A follow-on study 
demonstrated that individuals without experience of SMA exhibited greater support 
for preconception carrier screening compared to those with experience of SMA (12) 
(13). A key element in determining the acceptability of screening for particular 
conditions is understanding the views of people impacted by the condition. This study 
sought to ascertain the perceptions of parents of children with a genetic condition as 






Ethical approval  
This research project was approved by the Royal Children’s Hospital (RCH) Human 
Research Ethics Committee (HREC/46825/RCHM-2019).  
 
Study design 
A quantitative questionnaire-based study was undertaken to ascertain the views of 
parents of children with a genetic condition as to which types of conditions they 
believe should be included in carrier screening panels. An online survey was used as 
the vehicle for data collection and descriptive statistics were used to present the views 
of participants. This study is set within a pragmatic framework, which allows the 
research question to guide the research methods (14) and involves obtaining 
knowledge to inform practice and decision-making (15).  
 
Questionnaire development 
Drawing from two previous condition taxonomies (a means of categorising conditions 
based on disease characteristics), (16); (17) (Supplementary Table 1) seven types of 
conditions which vary in severity and include both treatable conditions and conditions 
for which no treatments have been proven to improve prognosis were selected for 
inclusion in the online questionnaire (Table 1). With the exception of hearing loss, the 
condition descriptions were general and the names of the conditions were not 
included in the questionnaire. This was to encourage participants to focus on the 
nature of the condition rather than specific diagnoses. 
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For each condition type, participants were asked: (i) whether they believe 
reproductive carrier screening should be offered for this type of condition; (ii) whether 
they would choose to have reproductive carrier screening for this type of condition 
and (iii) whether they would use reproductive options (prenatal diagnosis ‘PND’, pre-
implantation genetic diagnosis ‘PGD’ or donor gametes) to avoid having a child with 
this type of condition. Questions about religious views, genetic knowledge, 
reproductive choices and the genetic condition in the respondent’s family were also 
included. The questions relating to religion were taken from the Centrality of 
Religiosity Scale (CRS-5) (18) (See supplementary material for full questionnaire). The 
questionnaire was reviewed by several subject matter experts: Genetic Counsellors, 




Participants were included in this study if they were over the age of 18 and have a 
child with a genetic condition. Potential participants were invited to participate 
through RCH (Melbourne, Australia) outpatient clinics (neuromuscular, cystic fibrosis 
and metabolic medicine), the Genetic Support Network of Victoria (GSNV) and the 
Victorian Childhood Hearing Impairment Longitudinal Databank (VicCHILD). Potential 
participants from the cystic fibrosis clinic, Members of the GSNV and VicCHILD were 
emailed the study invitation by their respective coordinators. For clinics in which 
parent email addresses were not routinely collected (metabolic medicine and 
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neuromuscular), potential participants were invited to take part in the study by a 
researcher (LT) in the clinic waiting room. The study details were shared via the GSNVs 
social media outlets. 
 
Data analysis  
Cleaning and analyses of survey data collected via REDCap (19) were performed in 
STATA version 14 (20). Preliminary descriptive analyses generated frequency data. 
Categorical data were presented as frequencies and percentages, with comparison of 
the cohort (type of condition) group for religiosity, genetic knowledge and severity of 
the condition in the family undertaken using χ2 (chi-squared) tests. Partially complete 
questionnaires were included in the data analysis, hence the number of participants 
that completed each question varies throughout. Due to small numbers of ‘no’ and 
‘unsure’ responses to questions pertaining to participant views towards carrier 
screening for each type of condition, these were grouped into one category 
(“no/unsure”) for each question. 
 
An overall severity rating for the genetic condition affecting the participant’s 
child was devised. Three questions were used to ascertain the perceived severity of 
the participant’s child’s condition: (i) how would you rate the severity of your child’s 
condition; (ii) does the condition affect your child’s day to day life and (iii) does your 
child’s condition affect your daily life. The first question was scored from one to five, 
the second and third were scored from one to four, with the minimum and maximum 
scores possible being three and 13, respectively. Scores less than or equal to six were 
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classified as ‘mild’, scores from seven to 10 were classified as ‘moderate’ and scores 
greater than or equal to 11 were classified as ‘severe’. Overall scores were checked 
against the first question to ensure that the final classification reflected the parent’s 
assessment of the severity of their child’s condition.  
 
The religiosity questions (CRS-5) were scored as per Huber and Huber (2012). 
This scoring grouped participants as either ‘highly religious’, ‘religious’ or ‘not 
religious’. A genetic knowledge score was created to summarise the five questions 
pertaining to genetic knowledge. As there is limited research exploring knowledge 
related to carrier screening, these questions were modelled on a previous Australian 
study’s genetic knowledge questions (21). Participants who answered 0 or 1 question 
correctly were categorised as having ‘low’ genetic knowledge, participants who 
answered 2-3 questions correctly were categorised as having ‘moderate’ genetic 
knowledge and participants who answered 4-5 questions correctly were categorised as 
having ‘high’ genetic knowledge.  
 
Results 
One hundred and fifty people completed the questionnaire. Sixty-five individuals were 
invited to participate in clinic and approximately 1300 individuals were invited to 
participate via email. The participation rate is unable to be calculated as the number of 
individuals who were eligible to participate is unknown (some invited individuals 
would not have had a child with a confirmed genetic condition). Participants were 
mostly female (n=136/150, 90.7%) and aged 30 to 49 (110/150, 73.3%). The majority 
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of participants were born in Australia (n=129/150, 86.0%) and Caucasian (n=138/149, 
92.6%). Most participants had one child with a genetic condition (n=126/149, 84.6%) 
(Table 2). The most common conditions were cystic fibrosis (n=53/138, 38.4%), hearing 
loss (n=28/138, 20.3%) and Duchenne muscular dystrophy (n=9/138, 6.5%) (Table 3). 
 
Participants’ reproductive choices following their child’s diagnosis  
Most participants (n=113/144, 78.5%) reported being told that they had an increased 
chance of having another child with the same condition. Of these participants, 50.0% 
(n=55/110) reported their reproductive plans changed after receiving their child’s 
diagnosis. The most common change in reproductive plans was choosing not to have 
more children (Figure 1.1). Twenty-four (16.7%, N=144) participants indicated they did 
not have an increased chance of having another child with the same condition. Seven 
(30.4%, N=23) of these participants reported their reproductive plans changed after 
receiving their child’s diagnosis (Figure 1.2).  Seven (4.9%, N=144) participants were 
unsure if they had been told they had an increased chance of having another child with 
the same condition.  
 
Six participants (4.2%, N=142) indicated they or their partner have had a 
termination of pregnancy for the genetic condition affecting their child - (cystic 
fibrosis-4, beta-thalassaemia-1, Pendred syndrome-1). All participants who reported 
having had a pregnancy termination perceived their child’s condition as moderate 
(data not shown). 
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Participants’ views towards carrier screening for seven types of conditions 
For the scenarios presented, over 90% of participants supported offering screening for 
neuromuscular conditions (n=128/134, 95.5%), early fatal neurodegenerative 
conditions (n=130/141, 92.2%), chronic multi-system disorders (n=124/135, 91.9%) 
and conditions which cause intellectual disability (n=128/139, 92.1%). While the 
majority of participants also supported, to a lesser extent, inclusion of treatable 
metabolic conditions (n=120/138, 87.0%) and non-syndromic hearing loss (n=88/135, 
65.2%), views toward the inclusion of preventable adult-onset conditions (n=75/135, 
55.6%) were more mixed. The majority of participants indicated they would choose to 
undergo carrier screening for each of these types of conditions (Figure 2). For the 
scenarios presented, most participants indicated they would use reproductive options 
(PND, PGD or donor gametes) to avoid having a child with an early fatal 
neurodegenerative condition (n=113/139, 81.3%), a neuromuscular condition 
(n=108/135, 80.0%), a chronic multi-system disorder (n=100/134, 74.6%), a condition 
which causes intellectual disability (n=97/138, 70.3%) and a treatable metabolic 
condition (n=85/138, 61.6%), while approximately one third of participants said they 
would use reproductive options to avoid having a child with a preventable adult-onset 
condition (n=49/134, 36.6%) and non-syndromic hearing loss (n=44/135, 32.6%) 
(Figure 2). Almost half of the participants would choose to undergo carrier screening 
(n=62/131, 47.3%) for, and supported inclusion of, all seven types of conditions 
(n=64/137, 46.7%), but only 27.0% (n=34/126) of participants indicated they would use 
reproductive options to avoid having a child with all of the seven types of conditions. 
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We looked to see if there was a difference in views towards carrier screening 
between parents whose child had a condition which was consistent with one of the 
condition descriptions presented in the questionnaire and all other parents. Although 
no strong evidence of a difference was identified, the data suggests that a larger 
proportion of parents of children with hearing loss believe that non-syndromic hearing 
loss should be included in carrier screening, when compared to parents of children 
with other genetic conditions (n=26/134; n=61/134 78.8%; 60.4%, respectively, 
p=0.055). 
 
Factors which may influence views towards carrier screening  
Religiosity 
The majority of participants reported they were ‘not religious’ (n=73/131, 55.7%), 
38.2% (n=50/131) were ‘religious’ and 6.1% (n=8/131) were ‘highly religious’. Of those 
who identified with a religion (n=56/137, 40.9%), Catholicism was most common 
(n=18/51, 35.3%). There was no strong evidence of a difference between participants 
with respect to religiosity and views towards carrier screening (See supplementary 
tables 2.1 – 2.3). 
 
Genetic knowledge 
Seventy-two participants were found to have a high level of genetic knowledge 
(N=135, 53.3%), fifty (37.0%) had a moderate level of genetic knowledge and thirteen 
(9.6%) had a low level of genetic knowledge. No evidence of a difference was observed 
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between participants with respect to genetic knowledge and views towards carrier 
screening (See supplementary tables 3.1 – 3.3). 
 
Participants’ perceived severity of their child’s condition 
Participants were asked to rate the severity of their child’s condition and indicate the 
level of impact it has on their child’s life and on their own life. Seventy-six participants 
viewed their child’s condition as ‘moderate’ (N=143, 53.2%), twenty-nine (20.3%) 
viewed their child’s condition as ‘mild’ and thirty-eight (26.6%) viewed their child’s 
condition as ‘severe’ (Table 3). For all seven types of conditions presented, a smaller 
proportion of participants who viewed their child’s condition as severe thought that 
the condition should be included in carrier screening when compared to participants 
who viewed their child’s condition as moderate or mild (see supplementary table 4.1). 
The largest difference was observed between participant groups with respect to non-
syndromic hearing loss, with 76.9% (n=20) of the mild participant group, 72.0% (n=54) 
of the moderate group and 41.2% (n=14) of the severe group supporting its inclusion 
in carrier screening (p=0.003). 
 
Discussion 
Perceptions of the types of conditions to include in carrier screening panels 
This study is the first to examine the views of parents of children with a genetic 
condition towards carrier screening for different types of genetic conditions. 
Participants exhibited the most support for the inclusion of the more clinically severe 
types of conditions in carrier screening panels, those being early fatal 
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neurodegenerative conditions, neuromuscular conditions, chronic multi-system 
disorders and conditions which cause intellectual disability. Previous studies have 
highlighted the complexities associated with carrier screening and cautioned against 
the inclusion of milder conditions (9); (7), however, the participants in this current 
study appear to challenge the idea that only severe childhood-onset conditions should 
be included in carrier screening. A large proportion of participants believe that 
preventable adult-onset conditions and non-syndromic hearing loss should be included 
in carrier screening.  This could be explained by previous research which suggests that 
individuals with experiential knowledge are likely to perceive carrier screening as more 
relevant than those without a lived experience of a genetic condition (22).  
 
Our study found that participants with experience of cystic fibrosis were highly  
supportive of the inclusion of chronic multi-system disorders in carrier screening. 
Similarly, participants with experience of hearing loss were the most supportive of the 
inclusion of non-syndromic hearing loss in carrier screening. Previous studies have also 
demonstrated that individuals with experience of a particular genetic condition are 
often highly supportive of the inclusion of that condition in carrier screening (23); (12). 
Fifty-five percent of participants supported the inclusion of the preventable adult-
onset condition in carrier screening; this condition was modelled on 
haemochromatosis, although, no one with lived experience of haemochromatosis was 
included in this study. It would be useful to compare the views of participant’s in this 
study to the views of individuals with haemochromatosis, as their lived experience 
would differ to that of a parent of child with a genetic condition.  
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Types of conditions for which participants would choose to have screening 
The proportion of participants who would choose to have screening for each of the 
seven types of conditions was reflective of the proportion of participants who believe 
that each condition should be included in carrier screening. Two recent studies 
examined the views of the general population towards carrier screening and found the 
majority of participants would choose to have screening for adult onset or mild 
conditions (24); (25), analogous to the majority of the participants in our study. The 
Western Australian study found that over 80% of participants would undergo 
screening for moderate and severe conditions (24), whereas, a study conducted in the 
Netherlands found that only 34% of participants would have screening for serious, 
early-onset conditions (26). Interestingly, 23% of participants in the Netherlands study 
reported ‘not wanting to be bothered’ by knowing they were an ‘at-risk’ couple. The 
difference in views between participant’s in this current study and that of the 
Netherlands study is likely to be linked to participants’ experience of having a child 
with a genetic condition.  
 
Types of conditions for which participants would use reproductive options to avoid 
having an affected child 
This study found that most participants would use reproductive options (PND, PGD, 
donor gametes) for conditions perceived as more severe, as conditions become milder 
fewer participants indicated they would access reproductive options to avoid having 
an affected child. A recent US study of couples with an increased chance of having a 
child with a genetic condition pre-pregnancy, found that the majority of participants 
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intended to pursue actions to reduce the chance of an affected pregnancy; 91% for 
profound conditions, 77% for severe conditions and 65% for moderate conditions (27). 
Although the categories do not directly align with those in the current study, 
similarities exist between the two participant groups, with the majority of participants 
considering the use of reproductive options for the more severe types of conditions.  
 
Notably, this current study found that 32.1% of participants would use 
reproductive options to avoid having a child with non-syndromic hearing loss. In 
contrast, a previous Australian study looking at potential future uses of non-invasive 
prenatal testing (NIPT), found that only 5.2% of participants would terminate a 
pregnancy for deafness (28). This difference could be explained by the fact that 
participants in this current study could consider PGD and donor gametes as 
reproductive options in addition to termination of pregnancy (TOP), whereas the only 
reproductive option considered in the previous Australian study was TOP. Another 
possible explanation is that almost all participants in the previous study had no family 
history of a genetic condition. 
 
Factors which may influence views towards carrier screening  
This study identified differences between participants with respect to the severity of 
their child’s condition and their views towards carrier screening. Participants who 
viewed their child’s condition as severe were less likely to support the inclusion of non-
syndromic hearing loss and conditions which cause intellectual disability in carrier 
screening. A UK study examining the views of individuals with experience of bleeding 
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disorders (haemophilia A and B) found that participants generally had similar views 
towards carrier screening, irrespective of the perceived severity of their condition/the 
condition in their family (29). Other studies have found that there is a complex 
association between lived experience (severity of a condition) and views towards 
carrier screening and prenatal testing for that condition (30); (12). The difference in 
participants’ views between our study and other studies could be understood by the 
fact that the participants in the current study were asked about a range of conditions, 
whereas, previous studies asked participants only about the condition in their family.  
 
Unlike other studies, we did not find a significant evidence of a difference with 
respect to religiosity or genetics knowledge in terms of attitudes about carrier 
screening. Two Dutch studies which looked at the views of the general public towards 
carrier screening found that people who identified as religious were less likely to 
participate in carrier screening (31); (32). Nijmeijer et al. (2019) found that religious 
participants were less likely to believe that offering carrier screening was ethically 
acceptable (31). Although these populations differ to that of the current study, in that 
participants in the Dutch studies did not have experience of a genetic condition, it 
could be inferred that religiosity influences views towards carrier screening because 
some reproductive options may not align with commonly held religious beliefs. 
Although this current study did not identify any differences between participants with 
respect to genetic knowledge and views towards carrier screening, an Australian study 
found that genetic knowledge underscored attitudes towards undergoing carrier 
screening (24). Participants who had ‘good’ genetics knowledge were seven times 
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more likely to intend to undergo carrier screening, while participants with ‘high’ levels 
of genetic knowledge were only four times more likely to intend to undergo carrier 
screening (24). This suggests that individuals with higher levels of genetic knowledge 
could have a greater awareness of the broader implications of genetic testing. Level of 
genetic knowledge was tested more extensively in the other Australian study, with 21 
questions, whereas, our study used only five genetic knowledge questions, which may 
account for the difference between the two participant groups  
 
Limitations 
This study saw an overrepresentation of females of Caucasian background, which is 
possibly a reflection of the recruitment strategy and mode of data collection. 
Participation was limited to individuals who speak English and many invited 
participants were mothers accompanying their child to a hospital appointment. 
Additionally, when emails were used for recruitment, mothers were more often listed 
as the contact person. Individuals with lower literacy and/or technical skills may have 
been less likely to participate due the survey being administered online. 
 
This study captured participants with experience of a wide range of genetic conditions, 
with 38 different conditions represented. However, there were no participants whose 
child had a preventable adult-onset condition, in particular haemochromatosis. Some 
participant groups were small (for example parents of children with neuromuscular 
conditions), meaning that there is a limit to the generalisability of these results to 
other individuals with experience of similar genetic conditions. No cardiac conditions 
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or cancer syndromes were included amongst those surveyed. It would be useful to ask 
adults with these types of conditions their views towards carrier screening. 
 
Conclusion 
This study sought the views of parents of children with a genetic condition as to which 
types of conditions they believe should be included in carrier screening. It found that 
while the majority of participants support the inclusion of all seven types of conditions, 
as conditions become clinically milder, support for their inclusion decreased. Fewer 
participants indicated they would use reproductive options to avoid having a child with 
each of the types of conditions presented, however, this number increased as the 
severity of the condition increased. This suggests that the severity of the condition 
under consideration is a key factor in determining whether or not it should be included 
in carrier screening and in decision-making associated with carrier screening. There 
was a recurring association between participants’ views towards carrier screening and 
their lived experience of having a child with a genetic condition. This exemplifies the 
importance and value of including the views of those impacted by genetic conditions in 
discussions about carrier screening.  
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Figure Legends  
Figure 1.1: Changes in reproductive plans of participants who recall being informed of 
an increased chance of having another child with the same condition  
 
Figure 1.2: Changes in reproductive plans of participants who do not recall being 
informed of an increased chance of having another child with the same condition  
 





Table 1: Types of conditions included in the questionnaire  
 
Table 2: Demographics  
 
Table 3: Conditions reported by participants as affecting their child, with their 
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Supplementary material  
Supplementary table 1: A summary table of two condition taxonomies (a means of 
classifying conditions based on disease characteristics) (Korngiebel et al., 2016 & 
Lazarin et al., 2014). 
 
Supplementary tables 2.1-2.3: These tables present the data from the Chi2 analyses of 
views towards reproductive carrier screening for each type of condition and 
participants’ religiosity. This was used to determine whether there was a difference in 
views between participants who identified as religious/highly religious and those who 
identified as not religious.  
 
Supplementary tables 3.1-3.1: These tables present the data from the Chi2 analyses of 
views towards reproductive carrier screening for each type of condition and 
participants’ genetic knowledge. This was used to determine whether there was a 
difference in views between participants with low, moderate and high genetic 
knowledge. 
 
Supplementary tables 4.1-4.3: These tables present the data from the Chi2 analyses of 
views towards reproductive carrier screening for each type of condition and 
participants’ perceived severity of their child’s condition. Used to determine whether 
there was a difference in views between participants who viewed their child’s 
condition as mild, moderate and severe.  
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Questionnaire: The full questionnaire that participants completed. 
